Evaluation of Long-Term Sequelae After Thrombophlebitis, i.e. Deep Venous Thrombosis of the Lower Extremities
Deep Venous Thrombosis. Long-Term Results After Treatment With Either Low-Molecular -Weight Heparin or Unfractionated Heparin. Examinations of the Venous System.
1 other identifier
interventional
99
1 country
1
Brief Summary
The purpose of the study was to evaluate efficacy and safety of the new acute treatment of deep venous thrombosis by use of low-molecular-weight heparin compared with standard treatment using unfractionated heparin, especially concerning long-term morbidity.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_3
Started Oct 1993
Longer than P75 for phase_3
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 1993
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2004
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2004
CompletedFirst Submitted
Initial submission to the registry
February 25, 2008
CompletedFirst Posted
Study publicly available on registry
March 5, 2008
CompletedMarch 5, 2008
February 1, 2008
10.7 years
February 25, 2008
February 26, 2008
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Clinical evaluation of chronic venous insufficiency (CVI) - (Postthrombotic Syndrome) based on internationally accepted criteria.
Two years and 6 to 10 years
Study Arms (2)
1
ACTIVE COMPARATORUFH: patients treated with unfractionated heparin
2
EXPERIMENTALFH: patients treated with low-molecular-weight (fractionated) heparin
Interventions
UFH: Continuous i.v. infusion 100 IU/kg/4hrs initially and then adjusted to maintain APTT value 1.5 - 2.5 the pre-treatment value
FH (Tinzaparin): 175 iu/kg s.c. in the abdomen once daily
Eligibility Criteria
You may qualify if:
- First DVT with or without known risk factors except overt cancer
- Second DVT more than two years after the first if the patient was without clinical signs of CVI.
You may not qualify if:
- Contraindication to anticoagulation therapy
- Candidate to thrombectomy with arterious-venous fistula or thrombolytic therapy
- Known cancer at the time of the DVT diagnosis
- Patients unable to cooperate for anticoagulation therapy or manage the tests.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Aalborg University Hospitallead
- Aalborg Universitycollaborator
Study Sites (1)
Dept. of Haematology; Aalborg Hospital
Aalborg, North Denmark, 9000, Denmark
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Benedicte Laursen, MD, DMSc
Department of Haematology; Aalborg Hospital, 9100 Aalborg, Denmark
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
February 25, 2008
First Posted
March 5, 2008
Study Start
October 1, 1993
Primary Completion
June 1, 2004
Study Completion
June 1, 2004
Last Updated
March 5, 2008
Record last verified: 2008-02